C22.0
Conditions
Interventions
Group 1: Both at the beginning and during the course of therapy, CTC are determined at the following time points: Baseline, week 6, week 12.
Sponsors
Klinikum der Universität München, Campus Großhadern
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Male and female patients. 2. Age =18 years. 3. Patients with a histological/cytological or radiological diagnosis of HCC. 4. Patient informed consent.
Exclusion criteria
Exclusion criteria: 1. Inability to provide written informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prognostic value of baseline total CTC and baseline PD-L1-positive (PD-L1+) CTC | — |
Secondary
| Measure | Time frame |
|---|---|
| - Correlation of quantitative changes in CTC count and PD-L1+ CTC count with radiological response. - Correlation of total CTC and PD-L1+ CTC over the course of therapy with survival - Correlation of imaging and AFP with clinical endpoints (survival, response) and comparison of performance of imaging and AFP with CTC and PD-L1+ CTC | — |
Countries
Germany
Contacts
Public ContactNajib Ben Khaled
Medizinische Klinik und Poliklinik II, LMU Klinikum
Outcome results
None listed